TABLE 2.
Results for the base GEE model for amyloid‐negative and amyloid‐positive groups, respectively (A and B).
| Amyloid‐negative group | Amyloid‐positive group | ||||||
|---|---|---|---|---|---|---|---|
| (A) Bias Model | (B) Bias Model | ||||||
| Type III | Type III | ||||||
| Source | Wald chi‐square | df | Sig. | Source | Wald chi‐square | df | Sig. |
| (Intercept) | 2.10 | 1 | 0.15 | (Intercept) | 1568.10 | 1 | <0.001 |
| Tracer | 1.19 | 2 | 0.55 | Tracer | 0.73 | 2 | 0.70 |
| Clinical diagnosis | 0.85 | 2 | 0.65 | Clinical diagnosis | 22.26 | 2 | <0.001 |
| Reference region (RR) | 318.02 | 3 | <0.001 | Reference region (RR) | 102.40 | 3 | <0.001 |
| RR type | 198.87 | 1 | <0.001 | RR type | 54.62 | 1 | <0.001 |
| Target type | 59.22 | 1 | <0.001 | Target type | 9.83 | 1 | 0.002 |
| Space | 5.44 | 1 | 0.020 | Space | 47.04 | 1 | <0.001 |
| Tracer * RR | 224.01 | 6 | <0.001 | Tracer * RR | 116.78 | 6 | <0.001 |
| Tracer * RR type | 13.22 | 2 | 0.001 | Tracer * RR type | 10.53 | 2 | 0.005 |
| Tracer * Target type | 24.08 | 2 | <0.001 | Tracer * Target type | 30.34 | 2 | <0.001 |
| Tracer * Space | 56.53 | 2 | <0.001 | Tracer * Space | 86.85 | 2 | <0.001 |
| (C) Marginal means comparison | (D) Marginal means comparison | ||||
|---|---|---|---|---|---|
| Tracer | Mean (95% CI) | Tracer | Mean (95% CI) | ||
| FMM | 2.40 (−0.37 to 5.16) | FMM | 76.91 (71.01 to 82.80) | ||
| FBB | 2.77 (−1.92 to 7.46) | FBB | 74.06 (67.04 to 81.08) | ||
| FBP | 1.11 (−1.89 to 4.12) | FBP | 78.01 (72.03 to 83.98) | ||
| RR | Mean (95% CI) | ∆CL (95% CI) | RR | Mean (95% CI) | ∆CL (95% CI) |
|---|---|---|---|---|---|
| WCB | 4.70 (1.88 to 7.52) | Reference | WCB | 77.85 (74.03 to 81.66) | Reference |
| CGM | 5.53 (2.81 to 8.26) | 0.84 (0.19 to 1.48) | CGM | 76.26 (72.33 to 80.19) | −1.59 (−2.47 to −0.71) |
| WCB+BSTM | 2.36 (−0.49 to 5.21) | −2.34 (−2.67 to −2.00) | WCB+BSTM | 76.87 (73.08 to 80.67) | −0.97 (−1.54 to −0.40) |
| Pons | −4.22 (−7.50 to −0.94) | −8.92 (−10.63 to −7.48) | Pons | 74.32 (70.01 to 78.63) | −3.53 (−6.04 to −1.01) |
| RR type | Mean (95% CI) | ∆CL (95% CI) | RR type | Mean (95% CI) | ∆CL (95% CI) |
|---|---|---|---|---|---|
| GAAIN | 4.31 (1.43 to 7.20) | Reference | GAAIN | 77.66 (73.90 to 81.43) | Reference |
| Subject‐based | −0.13 (−2.94 to 2.68) | −4.44 (−5.06 to −3.82) | Subject‐based | 74.98 (71.16 to 78.80) | −2.68 (−3.39 to −1.97) |
| Target type | Mean (95% CI) | ∆CL (95% CI) | Target type | Mean (95% CI) | ∆CL (95% CI) |
|---|---|---|---|---|---|
| GAAIN | 0.36 (−2.49 to 3.22) | Reference | GAAIN | 75.76 (71.98 to 79.54) | Reference |
| Subject‐based | 3.82 (0.95 to 6.70) | 3.46 (2.58 to 4.34) | Subject‐based | 76.88 (73.08 to 80.70) | 1.13 (0.42 to 1.83) |
| Space | Mean (95% CI) | ∆CL (95% CI) | Space | Mean (95% CI) | ∆CL (95% CI) |
|---|---|---|---|---|---|
| MNI | 0.88 (−1.37 to 3.12) | Reference | MNI | 77.54 (73.64 to 81.45) | Reference |
| Native | 3.31 (−0.31 to 6.93) | 2.44 (0.39 to 4.48) | Native | 75.11 (71.43 to 78.79) | −2.43 (−3.13 to −1.47) |
Notes: The technical factors demonstrating statistical significance are highlighted in red. Marginal means and 95% confidence intervals for tracer, RR selection, RR type, target type, and quantification space for amyloid‐negative (C) and amyloid‐positive (D) groups. The last columns of (C) and (D) show differences between marginal means with respect to the reference technical design (RR: WCB; RR type: GAAIN; Target type: GAAIN; Space: MNI). Marginal mean differences exceeding ± 3CL are indicated in red.
Abbreviations: CGM, cerebellum gray matter; CL, Centiloid; FBB, 18F‐Florbetaben; FBP, 18F‐Florbetapir; FMM, 18F‐Flutemetamol; RR, Reference Region; WCB, whole cerebellum; WCB+BSTM, whole cerebellum plus brainstem.
Bold values indicate p‐values < 0.05.